Idarubitec 5 Injection 1's

Idarubitec 5 Injection 1's is an antineoplastic medicine used in the treatment of cancer. Cancer is a disease where the cells grow abnormally and divide uncontrollably. Idarubitec 5 Injection 1's is used in the treatment of Acute Myeloid Leukemia. Leukemia, also known as blood cancer, is the cancer of blood cells or blood-forming tissues. It causes excessive production of immature white blood cells by the bone marrow and reduces the body’s ability to fight infections.

Idarubitec 5 Injection 1's contains Idarubicin, which belongs to the class of anthracycline topoisomerase inhibitors. It inhibits the topoisomerase II enzyme by intercalating the DNA base pairs. This causes double helix DNA to be uncoiled, destroying DNA and RNA synthesis. Thus, Idarubitec 5 Injection 1's stops the multiplication of abnormal cells, leads to the growth of cells in an unbalanced way and causes cancer cell death. Idarubitec 5 Injection 1's is used in combination with other medicines for the treatment of acute myeloid leukemia.

Idarubitec 5 Injection 1's may cause certain side effects such as vomiting, nausea, mouth ulcers, loss of appetite, diarrhea, dizziness, weakness, stomach pain, headache, pale skin, difficulty urinating, fever, and pain at the site of injection. Most of these side effects of Idarubitec 5 Injection 1's do not require medical attention and gradually resolve over time. However, if the side effects persist or worsen, please consult your doctor. Idarubitec 5 Injection 1's is a parenteral preparation and will be administered by the oncology doctor. Hence, do not self-administer. Your doctor will decide the dose of the medicine based on the severity of the condition.

Idarubitec 5 Injection 1's should be avoided if you are allergic to it or any other component present in it. Inform your doctor about your complete medical and medication history before starting treatment with Idarubitec 5 Injection 1's. Idarubitec 5 Injection 1's is contraindicated for pregnant women due to serious embryo-fetal toxicity. Inform your doctor if you are pregnant, planning to become pregnant or breastfeeding. Inform your doctor if you have /had any pre-existing liver or kidney disease, bone marrow suppression, or heart disease, as it may cause serious adverse effects or worsen the condition. Avoid alcohol consumption with Idarubitec 5 Injection 1's as it may increase the risk of liver damage. This medicine is not recommended for children as safety and efficacy are not established.

Idarubitec 5 Injection 1's contains Idarubicin, which belongs to the class of anthracycline topoisomerase inhibitors. It inhibits the topoisomerase II enzyme by intercalating the DNA base pairs. This causes double helix DNA to be uncoiled, destroying DNA and RNA synthesis. Thus, Idarubitec 5 Injection 1's stops the multiplication of abnormal cells, leads to the growth of cells in an unbalanced way and causes cancer cell death.

• Vomiting
• Nausea
• Mouth ulcers
• Loss of appetite
• Dizziness
• Weakness
• Fever
• Pale skin
• Headache
• Difficulty urinating
• Injection site reactions
• Pain at the site of injection

Idarubitec 5 Injection 1's should be avoided if you are allergic to it or any other component present in it. Inform your doctor about your complete medical and medication history before starting treatment with Idarubitec 5 Injection 1's. Idarubitec 5 Injection 1's is contraindicated for pregnant women and breastfeeding women due to serious embryo-fetal toxicity. Inform your doctor if you are pregnant, planning to become pregnant or breastfeeding. Inform your doctor if you have /had any pre-existing liver or kidney disease, pre-existing bone marrow suppression, or pre-existing heart disease, as it may cause serious adverse effects or worsen the condition. Avoid alcohol consumption with Idarubitec 5 Injection 1's as it may increase the risk of liver damage. This medicine is not recommended for children as safety and efficacy are not established.

Drug-Drug Interactions: No interactions found.

Drug-Food Interactions: Idarubitec 5 Injection 1's may interact with alcohol. Therefore, avoid alcohol consumption with Idarubitec 5 Injection 1's as it may increase the risk of liver damage.

Drug-Disease Interactions: Inform your doctor if you have liver or kidney disease before starting treatment with Idarubitec 5 Injection 1's.

• Maintain a balanced diet including fruits and vegetables rich in nutrients and low-fat proteins like lean meats, fish and poultry.
• Drink plenty of water daily while taking Idarubitec 5 Injection 1's as some cancer therapies may cause dehydration.
• Exercise regularly and maintain a healthy body weight.
• Regularly wash your hands and avoid contact with people having infections.
• Quit smoking and alcohol consumption.

• Idarubitec 5 Injection 1's is intended for intravenous administration only. 
• This medicine should be administered only by a well-trained and experienced oncologist in a hospital setting.
• Regular blood tests are recommended while receiving Idarubitec 5 Injection 1's to monitor the number and type of cells in the blood, liver and kidney functioning.
• Cardiac function should be monitored carefully. Regular ECG should be done to check for any changes.

Acute Myeloid Leukemia (AML): It is a type of cancer that occurs in the bone marrow and blood. It abnormally increases the number of immature white blood cells. The symptoms include unexplained weight loss, excessive sweating, bone pain, frequent nosebleeds, heavier-than-normal periods in females, and shortness of breath. The risk factors include smoking and genetic or blood disorders.